Skilled Analyst Adds Value to Pharmaxis Board in Non-Executive Role

Must Read

The board of Pharmaxis Ltd has been bolstered by adding Hashan De Silva, a highly-regarded life sciences investment expert, as its latest non-executive director.

The appointment marks the start of De Silva’s new journey. He boasts experience as an associate healthcare analyst at Macquarie Group and leads healthcare analyst at CLSA Australia. Most recently, in February 2021, they stepped into their role as head of healthcare research for specialist healthcare fund Karst Peak Capital Ltd.

Previously, he had occupied a range of positions at Eli Lilly that concentrated on marketing and selling existing and novel pharmaceuticals.

We welcome Hashan to the Pharmaxis board,” chair Malcolm McComas said.

He has been an enthusiastic supporter of the company throughout his healthcare banking career, including more recently as head of healthcare research at Karst Peak Capital, where he conducted extensive diligence on our science which underpinned three separate investments in Pharmaxis,” Malcolm continued.

“Hashan’s knowledge of the Australian and international healthcare capital markets brings relevant insight and experience to the Pharmaxis board,” Malcolm added.

Pharmaxis has built an awe-inspiring drug discovery and development capability unique from other ASX-listed pharmaceutical companies. The clinical stage assets have generated exciting early data in diseases with high unmet need.” Sydney-based De Silva said.

Boasting a Bachelor’s Degree in Medicine and a Master’s Degree in Finance from the respected University of New South Wales, De Silva has given her expertise to CurveBeam  AI as their non-executive director based out of Melbourne and Philadelphia.  

Pharmaxis is devoted to uncovering innovative medicines to address inflammatory and fibrotic ailments, such as myelofibrosis, stromal-based cancers like pancreatic and liver cancer, NASH (nonalcoholic fatty liver), pulmonary fibrosis, CKD (chronic kidney disease), liver fibrosis plus the scarring caused by burns or other injuries.

Pharmaxis is dedicated to developing PXS-5505 for myelofibrosis, but it has also been trialled in other forms of cancer, such as liver and pancreatic. Their goals are to break down fibrotic tissue within tumours, thus intensifying existing chemotherapy treatments’ effects.

- Advertisement -spot_img
- Advertisement -spot_img
Latest News
- Advertisement -spot_img

More Articles Like This

- Advertisement -spot_img